FIGURE 4 from Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor–positive Breast Cancers for Targeted Treatment

Establish an IHC assay to detect NF1 protein in FFPE tumor samples. A, IHC was performed on a set of cell lines with varying degrees of NF1 (left). Protein lysates from indicated cell lines were also analyzed by immunoblot as shown on the right. B, IHC was performed to analyze a panel of ER⁺ PDOs with known NF1 status as determined by DNA sequencing. C, IHC was performed on one of the TMAs from the TMA Breast Cancer Continuum set, in which each TMA contains longitudinal samples from the same patient progressing from DCIS (D) to primary breast cancer (P). Kidney (K) was the normal tissue control on the TMA. Scale bar = 50 μm.